Literature DB >> 20520635

BCR and BCR-ABL regulation during myeloid differentiation in healthy donors and in chronic phase/blast crisis CML patients.

M Marega1, R G Piazza, A Pirola, S Redaelli, A Mogavero, I Iacobucci, I Meneghetti, M Parma, E M Pogliani, C Gambacorti-Passerini.   

Abstract

Chronic myeloid leukemia (CML) is caused by the BCR-ABL hybrid gene. The molecular mechanisms leading from chronic phase (CP) to blast crisis (BC) are not understood. However, both the presence and the levels of BCR-ABL seem to be important for CML progression. BCR-ABL is under the transcriptional control of BCR promoter. Here we focused on the gene expression control of BCR and BCR-ABL upon myeloid differentiation in healthy donors (HDs), CP and BC patients. As previously reported, BCR-ABL is downregulated during myeloid maturation in CP patients. A similar pattern was detected for BCR (but not for ABL) in CP-CML and in HD, thus suggesting that the two genes may be under a similar transcriptional control. In BC this mechanism is similarly impaired for both BCR-ABL and BCR. These data indicate the presence of an 'in trans' deregulated transcription of both BCR and BCR-ABL promoters, associated with CML progression.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20520635     DOI: 10.1038/leu.2010.101

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  19 in total

1.  Multifaceted actions of 8-amino-adenosine kill BCR-ABL positive cells.

Authors:  Rathi N Pillai; Lisa S Chen; Mary L Ayres; Billie J Nowak; Michael W Thomas; Elizabeth J Shpall; Michael J Keating; Varsha Gandhi
Journal:  Leuk Lymphoma       Date:  2012-04-23

Review 2.  Chronic myeloid leukemia: mechanisms of blastic transformation.

Authors:  Danilo Perrotti; Catriona Jamieson; John Goldman; Tomasz Skorski
Journal:  J Clin Invest       Date:  2010-07-01       Impact factor: 14.808

Review 3.  Cellular and Molecular Networks in Chronic Myeloid Leukemia: The Leukemic Stem, Progenitor and Stromal Cell Interplay.

Authors:  Danilo Perrotti; Giovannino Silvestri; Lorenzo Stramucci; Justine Yu; Rossana Trotta
Journal:  Curr Drug Targets       Date:  2017       Impact factor: 3.465

4.  Expression of BCR/ABL p210 from a knockin allele enhances bone marrow engraftment without inducing neoplasia.

Authors:  Samantha B Foley; Zacariah L Hildenbrand; Abigail A Soyombo; Jeffery A Magee; Yipin Wu; Katherine I Oravecz-Wilson; Theodora S Ross
Journal:  Cell Rep       Date:  2013-10-03       Impact factor: 9.423

Review 5.  Best Practices in Chronic Myeloid Leukemia Monitoring and Management.

Authors:  Simona Soverini; Caterina De Benedittis; Manuela Mancini; Giovanni Martinelli
Journal:  Oncologist       Date:  2016-03-31

Review 6.  Clinical Pharmacokinetics and Pharmacodynamics of Bosutinib.

Authors:  Richat Abbas; Poe-Hirr Hsyu
Journal:  Clin Pharmacokinet       Date:  2016-10       Impact factor: 6.447

7.  Spred2 modulates the erythroid differentiation induced by imatinib in chronic myeloid leukemia cells.

Authors:  Yuefeng Yang; Xiaoyun Liu; Fengjun Xiao; Shuya Xue; Qinqin Xu; Yue Yin; Huiyan Sun; Jie Xu; Hengxiang Wang; Qunwei Zhang; Hua Wang; Lisheng Wang
Journal:  PLoS One       Date:  2015-02-17       Impact factor: 3.240

8.  BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene.

Authors:  Nitesh Sharma; Vera Magistroni; Rocco Piazza; Stefania Citterio; Caterina Mezzatesta; Praveen Khandelwal; Alessandra Pirola; Carlo Gambacorti-Passerini
Journal:  Mol Cancer       Date:  2015-07-16       Impact factor: 27.401

9.  Histone demethylase RBP2 decreases miR-21 in blast crisis of chronic myeloid leukemia.

Authors:  Minran Zhou; Jiping Zeng; Xiaoming Wang; Xiangyu Wang; Tao Huang; Yue Fu; Ting Sun; Jihui Jia; Chunyan Chen
Journal:  Oncotarget       Date:  2015-01-20

10.  eIF4B is a convergent target and critical effector of oncogenic Pim and PI3K/Akt/mTOR signaling pathways in Abl transformants.

Authors:  Ke Chen; Jianling Yang; Jianning Li; Xuefei Wang; Yuhai Chen; Shile Huang; Ji-Long Chen
Journal:  Oncotarget       Date:  2016-03-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.